



STATE OF MARYLAND

DHMH

Office of Health Services
Medical Care Programs

Maryland Department of Health and Mental Hygiene

201 W. Preston Street • Baltimore, Maryland 21201

Robert L. Ehrlich, Jr., Governor – Arlene H. Stephenson, Acting Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM

Pharmacy Transmittal No. 169

Managed Care Organization Transmittal No. 40

March 7, 2003

TO: Managed Care Organizations
Pharmacists
Susan J. Tucker

FROM: Susan J. Tucker, Executive Director
Office of Health Services

NOTE: Please ensure that appropriate staff members in your organization are informed of the contents of this transmittal.

RE: Addition of Strattera™ (atomoxetine HCL) to the Mental Health Carve-Out

This transmittal is to inform you of a change in the mental health carve-out drugs which are payable as fee-for-service for recipients in managed care.

Effective February 1, 2003, Strattera™ (atomoxetine HCL), a new medication indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), has been reviewed and approved by the Mental Hygiene Administration's Pharmacy and Therapeutics committee for addition to the list of medications covered under the "Mental Health Formulary Carved-out of Managed Care and Payable as Fee-For-Service".

Claims for Strattera™ (atomoxetine HCL) should be billed through the point-of-sale system to Maryland Medicaid through First Health Services for both fee-for-service and managed care organization recipients. If a Managed Care Organization's Pharmacy Benefits Manager (PBM) paid for this drug the pharmacy must void the claim or the PBM must have the claim voided. In order to receive payment the claim must be resubmitted to Maryland Medicaid through First Health Services' Point of Sale (POS) system within the nine-month billing statute of limitations.

Questions concerning this transmittal should be directed to the Division of Pharmacy and Clinic Services at 410-767-1455.